PTO/SB/08a (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

-U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

M.	Under the Paperwo	K Reduction Act of	1995, no persor	ns are required to i	espond to a collection of informati-	on unless it displays a valid OMB control number.		
N. S.	AC. ball to say say.	4.4.0.A.IDTO			Complete if Known			
	Substitute for form	1449A/PTO			Application Number	10/567,424		
	INFORM	ATION DI	SCI OSI	IDE	Filing Date	12/9/2008		
	Ma.				First Named Inventor	Mulley et ai.		
	SIAIEN	MENT BY	APPLICA	AIN I	Art Unit	1649		
	(Ne	as many sheets as	s necessary)		Examiner Name	Kolker, Daniel E.		
Shee	et 🔪	1	of	3	Attorney Docket Number	1386/23		

			U.S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number - Kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-2010/0138623	06-03-2010	Mulley et al.	
	2	US-2010/02035 <b>4</b> 8	08-12-2010	Petrou et al.	
			Nichting Old House Mark No. 10 Indicated by Arthur Mark Mark Mark Mark Mark Mark Mark Mar		
***************************************			······································		
		***************************************	***************************************	/	
· his big hij obis pilotoji (w. jak memakansus in					
		NORMORER MEDICALISA (ROMANICA O ROMANICA (ROMANICA ROMANICA ROMANICA ROMANICA ROMANICA (ROMANICA ROMANICA ROMA			
·*************************************		макчанаминулганыминаламиным этом немененалаламиналаламиналаламиналаламиналаламиналаламиналаламиналаламиналалам	<u> </u>		
		***************************************			
***************************************		Marylandala ayanda kullala kullala kullala kula kullala kulla kullala kullala kullala kullala kulla kullala ku			
		MID NO DIMO NOME MEMORINA MENANDE MEMORINA MEMORINA MENORIA MENENDE MEMORINA	N. C.		

		FO	REIGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-D-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	<u>.</u>				манаснамиция развичения канания по пределения на пределения на пределения на пределения на пределения на пред	igspace
					A DESCRIPTION OF STREET, STREE	-
				The state of the s		$\vdash$
Examiner Signature				Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCAL

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitut	te for form 1449B/PTO				Complete if Known	
M				Application Number	10/567,424	
INF	RMATION DIS	CLOS	SURE	Filing Date	12/9/2008	
	ATEMENT BY AI			First Named Inventor	Mulley et al.	
312	CIENTENI DI AI	FFLIC	/AIN I	Art Unit	1649	
	(Use as many sheets as n	ecessary)		Examiner Name	Kolker, Daniel E.	
Sheet	1/2	of	3	Attorney Docket Number	1386/23	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, purnal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>				
	3	Beaumanoir, In: Epileptic Syndromes in Infancy, Childhood and Addescence, 2 <sup>nd</sup> ed., Roger J BM et al., editor, London: John Libbey & Co. Ltd., pgs. 113-136 (2002).					
	4	Blume, W. T., "Childhood brain tumors presenting as chronic uncontrolled focal seizure disorders," Ann. Neurol., Vol. 4, pgs. 541-547 (1978).					
	5	Blume et al., "Childhood Brain Tumors Presenting as Chronic Uncontrolled Focal Seizure Disorders," Annals of Neurology, Vol. 12, No. 6, pgs. 538 541 (December 1982).					
	6	Burnstine et al., "Multifocal Independent epileptiform discharges in children: Ictal correlates and surgical therapy," Neurology, Vol. 41, pgs. 1223-1228 (1991).					
	7	Doose et al., "Severe idiopathic generalized epilepsy of infancy with generalized tonic-clonic seizures," Neuropediatrics, Vol. 29, Igs. 229-238 (1998).					
	8	Dravet et al., In: Epileptic Syndromes in Triancy, Childhood and Adolescence, 3 <sup>rd</sup> ed., Eastleigh: John Libbey & Co., Ltd. Pgs. of 103 (2002).					
	9	GenBank Accession No. AC0100127, NCBI Database, National Center for Biotechnology Information, National Library of Medicine, NIH (Bethesda, MD, USA), GI: 11597116, 09 May 2001.					
MONTH MATERIAL PROPERTY COMMENTS	10	GenBank Accession No. AC0100127, NCBI Database, National Center for Biotechnology Information, National Library of Medicine, NIH (Bethesda, MD, USA), GI: 11597116,08 April 2005					
Name and the state of the state	11	Genbank accession number AF225985.					
	12	Interview Summary forresponding to U.S. Patent Application Serial No. 12/696,769 dated February 18, 2011.					
	13	Lossin C. Brain and Development (2009) vol. 31, pages 114-130.					
	14	Malik et al., 'Multifocal Independent Spike Syndrome (MISS): An Identifiable and Predictable Electroclinical Syndrome," Neurology, Vol. 39, Suppl. 1, pg. 189 (1989).					
	15	Markand, O. N., "Slow spike-wave activity in EEG and associated clinical features: often called 'Lennox' or 'Lennox-Gastaut' syndrome," Neurology, Vol. 27, pgs. 746-757 (1977).					

	 <i>Y</i>	<b>.</b>	
Examiner	Date	WAR.	
Signature	Considered	BAAA	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

<sup>&</sup>quot;EXAMINER: Initial in reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation ir not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS DRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA
O a collection of information unless the design of the commence of the com Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitu	ite for form 1449B/PTO				Complete if Known	
A. A.				Application Number	10/567,424	
INF	ORMATION DISC	CL OS	SURF	Filing Date	12/9/2008	
	ATEMENT BY AF			First Named Inventor	Mulley et al.	
317	AID NEW DIVE			Art Unit	1649	
	(Use as many sheets as ne	ecessary)		Examiner Name	Kolker, Daniel E.	
Sheet	13	of	3	Attorney Docket Number	1386/23	

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), alle of the item (book, magazine, purnal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>					
	16	Noriega-Sanchez et al., "Clinical and electroencephalographic correlation of independent multifocal spike discharges," Neurology, Vol. 26, pgs. 667-672 (1976).						
	17	Notice of Allowance corresponding to U.S. Patent Application Serial No. 12/696,769 dated March 21, 2011.						
	18	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 12/636,769 dated August 5, 2010						
	19	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 12/696,769 dated November 29, 2010.						
	20	Office Action corresponding to U.S. Patent Application Serial No. 12/767,523 dated May 16, 2011.						
	21	Office Action corresponding to U.S. Patent Application Serial No. 11/922,377 dated May 25, 2011.						
	22	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 12/767,523 cated August 25, 2011.						
	23	Ohmori et al., "Is phenotype difference in severe myoclonic epilepsy in infancy related to SCN1A mutations?," Brain Dev., Vol. 25, pgs. 488-433 (2003).						
•	24	Orkin et al."Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy", NIH, 1995						
	25	Thomas et al., "Progress and Problems with the Use of Viral Vectors for Gene Therapy," Nature, Vol. 4, pgs 346-358 (2003).						
en en en ble kræde en en blek i skiden biske	26	Verma et al., "Gene therapy promises, problems and prospects," Nature, Vol. 389, pgs. 239-242 (1997).						
	27	Yamatogi et al., "Severe Epilepsy with Multiple Independent Spike Foci," J. Clin. Neurophysiol., Vol. 20, pgs. 442-448 (2003).						

	#	,		
Examiner		Date	te	
Signature		Con	nsidered	Mark the second

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial in regrence considered, whether or not citation is in compliance with MPET 605. Draw line through citation in the initial network of the considered. Include copy of this form with next communication to applicant.

Applicant's unique station designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments of the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademan Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.